A universal predictive and mechanistic urinary peptide signature in acute kidney injury

Archive ouverte

Piedrafita, Alexis | Siwy, Justyna | Klein, Julie | Akkari, Amal | Amaya-Garrido, Ana | Mebazaa, Alexandre | Sanz, Anna Belen | Breuil, Benjamin | Montero Herrero, Laura | Marcheix, Bertrand | Depret, François | Fernandez, Lucie | Tardif, Elsa | Minville, Vincent | Alves, Melinda | Metzger, Jochen | Grunenwald, Etienne | Feuillet, Guylène | Buléon, Marie | Brunet, Manon | Mayeur, Nicolas | Casemayou, Audrey | Labaste, François | Grossac, Julia | Mischak, Harald | Ortiz, Alberto | Gazut, Stéphane | Schanstra, Joost | Faguer, Stanislas

Edité par CCSD ; BioMed Central -

International audience. Background The delayed diagnosis of acute kidney injury (AKI) episodes and the lack of specificity of current single AKI biomarkers hamper its management. Urinary peptidome analysis may help to identify early molecular changes in AKI and grasp its complexity to identify potential targetable molecular pathways.Methods In derivation and validation cohorts totalizing 1170 major cardiac bypass surgery patients and in an external cohort of 1569 intensive care unit (ICU) patients, a peptide-based score predictive of AKI (7-day KDIGO classification) was developed, validated, and compared to the reference biomarker urinary NGAL and NephroCheck and clinical scores. Results A set of 204 urinary peptides derived from 48 proteins related to hemolysis, inflammation, immune cells trafficking, innate immunity, and cell growth and survival was identified and validated for the early discrimination (< 4 h) of patients according to their risk to develop AKI (OR 6.13 [3.96–9.59], p < 0.001) outperforming reference biomarkers (urinary NGAL and [IGFBP7].[TIMP2] product) and clinical scores. In an external cohort of 1569 ICU patients, performances of the signature were similar (OR 5.92 [4.73–7.45], p < 0.001), and it was also associated with the in-hospital mortality (OR 2.62 [2.05–3.38], p < 0.001). Conclusions An overarching AKI physiopathology-driven urinary peptide signature shows significant promise for identifying, at an early stage, patients who will progress to AKI and thus to develop tailored treatments for this frequent and life-threatening condition. Performance of the urine peptide signature is as high as or higher than that of single biomarkers but adds mechanistic information that may help to discriminate sub-phenotypes of AKI offering new therapeutic avenues.

Suggestions

Du même auteur

Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease

Archive ouverte | Amaya-Garrido, Ana | CCSD

International audience. Vascular calcification is an important risk factor for cardiovascular (CV) mortality in patients with chronic kidney disease (CKD). It is also a complex process involving osteochondrogenic di...

Performances of acute kidney injury biomarkers vary according to sex

Archive ouverte | Faguer, Stanislas | CCSD

International audience. ABSTRACT Background Before implementing individualized strategies to treat acute kidney injury (AKI), identifying clusters of patients with divergent pathophysiological mechanisms, diagnosis ...

The tryptophan pathway and nicotinamide supplementation in ischaemic acute kidney injury

Archive ouverte | Piedrafita, Alexis | CCSD

International audience. Background. Down-regulation of the enzymes involved in tryptophan-derived nicotinamide (NAM) adenine dinucleotide (NAD$^+$) production was identified after acute kidney injury (AKI), leading ...

Chargement des enrichissements...